T. Rowe Price Associates
PRQR icon

T. Rowe Price Associates’s ProQR Therapeutics PRQR Stock Holding History

T. Rowe Price Associates’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-343,925
Closed -$3.13M – 2544
2019
Q2 		$3.13M Sell
343,925
-119,500
-26% -$1.41M ﹤0.01% 1471
2019
Q1 		$6.43M Sell
463,425
-17,000
-4% -$254K ﹤0.01% 1375
2018
Q4 		$7.58M Buy
+480,425
New +$8.82M ﹤0.01% 1348

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates's PRQR Position: Q3 2019 in Review

T. Rowe Price Associates sold out of ProQR Therapeutics (PRQR) in Q3 2019, closing a stake of 343,925 shares — an estimated $3.13M sold.

T. Rowe Price Associates first reported a position in PRQR in Q4 2018 and held it in 3 quarters. The position peaked at $7.58M in Q4 2018. 50 funds tracked by Wall St. Rank hold PRQR as of Q3 2019.

  • T. Rowe Price Associates reported no remaining ProQR Therapeutics position as of Q3 2019 after selling out during the quarter.
  • T. Rowe Price Associates sold 343,925 ProQR Therapeutics shares in Q3 2019, an estimated $3.13M.
  • T. Rowe Price Associates first reported a position in ProQR Therapeutics in Q4 2018 and held it in 3 quarters.
  • T. Rowe Price Associates's ProQR Therapeutics position peaked at $7.58M in Q4 2018.
  • 50 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2019.

Based on T. Rowe Price Associates's 13F filing for Q3 2019, filed 14 Nov 2019.